Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 February 2024 | Story Lacea Loader | Photo SUPPLIED
Prof Bob Frater
The late Prof Robert Frater, after whom the Robert WM Frater Cardiovascular Research Centre at the UFS was named.

The Robert WM Frater Cardiovascular Research Centre (the Frater Centre) at the University of the Free State (UFS) received the sad news of the passing of Prof Robert (Bob) Frater at the age of 95 on 29 January 2024 in New York. 

“Prof Frater was and will continue to be regarded as an international icon in heart surgery, especially in mitral valve repair where he described the use of artificial chordae, which is still the international standard today.  Since 2006, he has been intimately involved in the establishment of the research programme in the Department of Cardiothoracic Surgery at the UFS, which culminated in the establishment of the Frater Centre in 2015. This would not have been possible without the combined efforts of the UFS and the generous financial support by Glycar – a Pretoria-based company established by Prof Frater,” says Prof Francis Smit, Director of the Robert WM Frater Cardiovascular Research Centre and Head of the Department of Cardiothoracic Surgery at the UFS.

Prof Frater was born in Cape Town and attended Bishops Diocesan College from 1937 to 1946. He excelled at school, both academically and as a sportsman. He was a prefect, captained the tennis team, and played first team rugby. He studied medicine at the University of Cape Town (UCT), achieving a first class in Surgery. He qualified as a cardiothoracic surgeon at the Mayo Clinic and after a stint back in Cape Town, spent the rest of his illustrious career at the Einstein and Montefiore university hospitals in New York. Despite this distance, Prof Frater always maintained and cherished his South African roots, palpably demonstrated by his notable collection of Africana books and art.

“He was an inspiring mentor and educator, and constructively influenced generations of cardiothoracic surgeons trained at the UFS and internationally. His enthusiasm for scientific research and deep understanding of heart valves and tissue engineering have largely determined the research focus of the Frater Centre to this day.  He received an honorary doctorate in Medicine from the UFS in 2011 in recognition of his immense contributions to cardiothoracic surgery during his lifetime. Apart from his international recognition and awards, the other outstanding award he received and cherished in South Africa, was the Robert Gray Medal from his old school, Bishops Diocesan College,” says Prof Smit.

At the UFS, he was Prof Smit’s promotor for his PhD on human heart valve transplants (homografts) and inspired an additional five PhD studies (four of which addressed tissue engineering, and one in re-designing a poppet mechanical heart valve, which was named the Frater valve).  Studies on heart valve mechanics and hydrodynamics conducted at the Frater Centre in support of these valve developments resulted in three cum laude Master of Engineering degrees awarded by Stellenbosch University.  Over time, the Robert WM Frater Cardiovascular Research Centre’s research output steadily increased in scope and quality, mainly due to the values of curiosity, excellence, integrated interdisciplinary collaborative teams, integrity, and mutual respect instilled by Prof Bob Frater.

“Prof Frater was always received ostentatiously in Bloemfontein. The registrars crowded around him, our research team was inspired, wisdom was gained from his vast experience in surgery and research, and no-one was left untouched by the deep humanity of this remarkable man. He was truly an exceptional individual, and a memorable South African.”

We wish to express our sincerest condolences and deepest sympathy to his wife Eileen, sons Hugh, Dirk, and the rest of the family,” says Prof Smit.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept